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Abstract The content of plasma and arterial interstitial fluid in
water-soluble antioxidants makes it unlikely for low-density
lipoprotein (LDL) to oxidize by the oxidation mechanisms most
frequently discussed. By aggregation of LDL in the presence of
chondroitin-4-sulfate (C-4-S), but not with chondroitin-6-sulfate
or sphingomyelinase, a complex arises which can oxidize in the
presence of 20 WM ascorbate and 300 WM urate. This oxidation
sensitivity even persists after the gel-filtration of an LDL/C-4-S/
Cu2+ complex, indicating entrapment of Cu2+ within. This
corresponds well to the known ability of C-4-S to bind copper
ions and is a potential mechanism by which LDL oxidation in the
arterial intima is facilitated after prolonged retention by the
extracellular matrix. ß 2002 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
Key words: Atherosclerosis ; Lipid peroxidation;
Antioxidant; Extracellular matrix; Glycosaminoglycan;
Chondroitin-4-sulfate
1. Introduction
The oxidation of low-density lipoprotein (LDL) is supposed
to be a crucial event in atherogenesis (for a review see [1]) but
it remains unclear to date by which mechanisms and by which
oxidants lipoproteins are oxidized in the arterial wall in vivo.
Recently, it has clearly been shown that lipoproteins do not
oxidize [2] in the presence of water-soluble antioxidants, such
as ascorbate (AscH) and urate (UA), which are present in the
subendothelial lining £uid at similar concentrations as in plas-
ma (20^100 WM AscH and 300^400 WM UA) [3]. However,
several lines of evidence indicate a large extent of lipid peroxi-
dation in atherogenesis [4], hence the question arises by which
mechanism(s) LDL could be oxidized indeed in an antioxi-
dant-rich environment. One such possibility for lipid peroxi-
dation in the arterial wall is by aggregation, under which
circumstances metal ions found in atherosclerotic deposits
[5], such as Cu2 and Fe3, might become trapped within
aggregates, in addition to the prolonged retention of such
aggregates, which itself is likely to favor oxidation. Aggrega-
tion of LDL has been shown to arise from shear stress (e.g. by
vortexing or shaking) and is enhanced by many factors, such
as glycosaminoglycans and proteoglycans [6], or by enzymes,
e.g. sphingomyelinase (SMase) [7]. Moreover, aggregates of
LDL with glycosaminoglycans and proteoglycans were previ-
ously found to oxidize more easily than isolated LDL [8,9].
However, it has never been investigated whether and how
such aggregates can oxidize in the presence of water-soluble
antioxidants.
Copper ions have been used frequently as a model to induce
oxidation of LDL but their relevance for oxidation in vivo has
been questioned. Nevertheless, there is increasing evidence
that Cu2 is found in atherosclerotic plaque either in free
form [10], colocalizing with iron and ceroid [11] or bound to
protein, such as ceruloplasmin. Such ceruloplasmin-bound
Cu2 may be redox-active by itself [12], even in the presence
of antioxidants [13], or become liberated by the low pH at
in£ammatory sites [5] or through the action of nitric oxide
[14].
By aggregation of LDL not only the ratio of surface to
volume of the lipoproteins is decreased unfavorably for aque-
ous antioxidants in order to prevent oxidation, also Cu2 ions
eventually trapped within the aggregates might start redox-
cycling, a process which is thought to be triggered by reduc-
tion of the metal by K-tocopherol [15,16]. It might be en-
hanced if there is no interference by aqueous antioxidants,
which may lead to the regeneration of K-tocopherol by
AscH, for example.
12/15-Lipoxygenase (12/15-LOX) has been shown to be in-
volved in the formation of atherosclerotic lesions [17], and
recently it has been demonstrated in an apoE-knockout
mouse model that the expression of 12/15-LOX might con-
tribute considerably to the formation of atherosclerotic
plaques [18]. It has been shown that ‘seeding’ of LDL with
hydroperoxides produced by incubation with 12/15-LOX
leads to enhanced sensitivity of LDL to Cu2-induced oxida-
tion [19].
Therefore we wanted to test the hypothesis that aggregation
of LDL with glycosaminoglycans can lead to facilitated oxi-
dation even in the presence of high concentrations of water-
soluble antioxidants, which would otherwise prevent LDL
oxidation.
2. Materials and methods
All materials were of analytical grade or better, and from Sigma or
Merck (Vienna, Austria), unless speci¢ed otherwise. Chondroitin-4-
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sulfate (C-4-S) and chondroitin-6-sulfate (C-6-S) were from Sigma (C-
4-S from bovine trachea, 70%, containing 30% C-6-S; C-6-S was from
shark cartilage, 90%, 10% C-4-S) and used as obtained from the
manufacturer. AscH was from Loba (Fischamend, Austria), 12/15-
LOX from rabbit reticulocytes was a kind gift of Prof. Dr. Hartmut
Ku«hn, Charite¤, Berlin, Germany.
Experiments shown are representative of at least two independent
experiments.
2.1. Isolation of human LDL
LDL was prepared from pooled ethylenediaminetetraacetic acid
(EDTA) plasma of healthy volunteers of both sexes by ultracentrifu-
gation in a single-step discontinuous density gradient in a Beckman
NVT65 rotor, as described [20]. Prior to use, LDL was stored in an
evacuated glass vial under argon at 4‡C for a maximum of 2 weeks.
LDL concentration was determined from its total cholesterol content,
using the CHOD-PAP enzymatic test kit (Boehringer-Mannheim,
Germany), assuming a molar mass of LDL of 2.5 MDa and a choles-
terol content of 32.2 wt%.
2.2. Monitoring of LDL oxidation by low-level chemiluminescence
(LL-CL)
Prior to oxidation of LDL, EDTA and KBr were removed by gel-
¢ltration as described [21]; brie£y, 1 ml of LDL solution was loaded
onto a Bio-Rad Econo-Pac 10DG column (Bio-Rad, Richmond, CA,
USA), and eluted with 3 ml PBS (phosphate-bu¡ered saline: 160 mM
NaCl, 10 mM Na-phosphate, pH 7.4; containing 2 mM CaCl2and
4 mM MgCl2), collecting LDL in the last ml of eluent. Oxidation
was performed (after addition of antioxidants, glycosaminoglycans
and enzymes, if applicable) at 37‡C by addition of a 100 WM solution
of CuSO4to a 0.3 WM solution of LDL in PBS, to give a ¢nal con-
centration of 4.3 WM Cu2.
LL-CL was measured in a Lucy 1 luminometer (Anthos Labtech
Instruments, Salzburg, Austria) equipped with a photon counting
photomultiplier (sensitivity ranging from 300 to 700 nm). Integration
time for each data point was set to 90 s. The assays were performed at
37‡C, in a white microplate. The source of LL-CL is the decay to the
ground state of triplet carbonyl compounds produced by recombina-
tion of lipid peroxyl radicals to non-radical products [22]. It was
shown that the lag time of LL-CL closely corresponds to the lag in
the formation of conjugated dienes, and that the intensity of LL-CL is
proportional to the square of the oxidation rate. Its advantage over
spectrophotometric detection of conjugated dienes is that its perform-
ance is not impeded by the presence of UV-absorbing compounds in
the medium. Experiments were performed at least twice.
2.3. Aggregation of LDL
LDL was aggregated in the presence of C-4-S or C-6-S in the
presence of Ca2 and Mg2 (2 mM and 4 mM, required for the
activity of 12/15-LOX and SMase, respectively) and/or vortexing, us-
ing the shake mode of the luminometer. Aggregation by SMase
(Bacillus cereus) was performed essentially as described in [7], except
that the bu¡er was PBS (plus 2 mM CaCl2, 4 mM MgCl2).
The aggregation of lipoproteins was monitored photometrically
measuring the increase of turbidity at 680 nm.
3. Results
3.1. Oxidation of LDL aggregated by shear forces and by the
action of SMase
LDL (0.3 WM) was aggregated either by vigorous shaking in
the luminometer (1 min) or by preincubation with SMase (up
to 50 mU, 30 min, 37‡C) in the presence of 20 WM AscH and
300 WM UA before the addition of Cu2. Fig. 1 shows that
compared to the antioxidant-free control, the presence of
AscH and UA considerably prolonged the lag phase of
LDL oxidation, about 20-fold. Aggregation by shaking did
not signi¢cantly increase the oxidizability of LDL in the pres-
ence of AscH and UA. Neither was a prooxidant e¡ect ob-
served after enzymatic aggregation with SMase, at high con-
centrations of SMase the enzyme even prolonged the lag
phase. Interestingly, inclusion of 20 WM AscH and 300 WM
UA increased LL-CL intensity by about 60% (corresponding
to about 30% increase in oxidation rate, as LL-CL is propor-
tional to the square of the oxidation rate).
3.2. E¡ect of aggregation by glycosaminoglycans, C-4-S, and
C-6-S
LDL (0.3 WM) was oxidized by incubation with 4.8 WM
Cu2 after addition of C-6-S (Fig. 2A) or C-4-S (Fig. 2B) at
0.25^1 mg/ml, in the presence of 20 WM AscH and 300 WM
UA. A signi¢cant decrease of the lag time before onset of
rapid oxidation compared to the antioxidant-containing con-
trol (trace B) was observed, strongly depending on the con-
centration of C-4-S. C-6-S was considerably less e¡ective than
C-4-S and did not exhibit a pronounced concentration depen-
dence like C-4-S.
To make sure that aggregation is responsible for the ob-
served e¡ects, LDL (3^4 mg/ml), C-4-S (1.3 mg/mg LDL) and
Cu2 (6.4 WM/mg LDL) were thoroughly mixed and brie£y
vortexed. The mixture was gel-¢ltrated as described in Section
2.2 and diluted to give 0.3 WM LDL (leading to dilutions of
the other constituents comparable to the experiments de-
scribed above), and AscH and UA added to give 20 WM
and 300 WM, respectively. Oxidation was monitored by LL-
CL, of the complex alone or in the presence of 100 mU chon-
droitinase ABC, without addition of further Cu2. Fig. 3
shows that the gel-¢ltrated complex oxidized in the presence
of the antioxidants (trace A), unless the integrity of the gly-
cosaminoglycan was destroyed with chondroitinase (trace B).
3.3. Increased susceptibility to oxidation of LDL aggregates
with C-4-S and SMase after seeding with 12/15-LOX
Incubation with 12/15-LOX has been shown to increase the
content of LDL in hydroperoxides, in particular cholesteryl
ester hydroperoxides [19]. Such ‘seeding’ has been proposed to
be a potential mechanism for the atherogenicity of 12/15-
LOX. When non-aggregated LDL was incubated with 12/15-
LOX for 30 min at 37‡C and then aggregated by addition of
Fig. 1. LDL oxidation after aggregation by shear forces and SMase.
LDL was incubated at 0.3 WM, oxidation was induced by addition
of 4.5 WM Cu2. (A) Control, (B) 20 WM AscH+300 WM UA,
(C) like (B), but shaken for 1 min, (D) like (B), but after 30 min
preincubation with 50 mU SMase.
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SMase, a strong prooxidant e¡ect of 12/15-LOX was found
(Fig. 4) after initiating lipid peroxidation by addition of Cu2.
Practically identical e¡ects were observed whenever LDL was
aggregated ¢rst by C-4-S (or SMase ^ not shown for clarity)
and then incubated with 12/15-LOX. It should be noted that
incubation with 12/15-LOX does not increase oxidizability of
non-aggregated LDL by Cu2 in the presence of AscH and
UA (not shown), hence under these conditions, 12/15-LOX-
derived lipid hydroperoxides enhance the oxidation sensitivity
of the complex only.
4. Discussion
The interaction of lipoproteins with glycosaminoglycans
and proteoglycans of the endothelial extracellular matrix has
been suggested to be one of the key factors in atherogenesis
[23,24]. Increased retention of LDL in the subendothelial
space of the arterial intima, and consequentially a prolonged
exposure to oxidants was hypothesized to be involved in the
‘response-to-retention’ hypothesis. It has been demonstrated
earlier that the interaction of LDL with glycosaminoglycans
and proteoglycans (in particular those of C-6-S) increases its
susceptibility towards oxidation, albeit this e¡ect was ob-
served only in the absence of water-soluble low-molecular
Fig. 2. LDL oxidation in the presence of C-4-S and C-6-S. LDL
was incubated as in Fig. 1. A: (A) Control, (B) as (A) plus 20 WM
AscH and 300 WM UA, (C) as (B) plus 0.25 mg/ml C-6-S, (D) as
(B) plus 0.5 mg/ml C-6-S, (E) as (B) plus 1.0 mg/ml C-6-S.
B: (A) Control, (B) as (A) plus 20 WM AscH and 300 WM UA,
(C) as (B) plus 0.25 mg/ml C-4-S, (D) as (B) plus 0.5 mg/ml C-4-S,
(E) as (B) plus 1.0 mg/ml C-4-S.
Fig. 3. LDL (3^4 mg/ml), C-4-S (1.3 mg/mg LDL) and Cu2 (6.4
WM/mg LDL) were brie£y vortexed, gel-¢ltrated and then diluted to
0.3 WM LDL. Oxidation was monitored in the presence of 20 WM
AscH and 300 WM UA (without further addition of Cu2), in the
absence (A) and presence of chondroitinase ABC (B).
Fig. 4. LDL oxidation after aggregation and preincubation with 12/
15-LOX. LDL was oxidized as in Fig. 1. (A) Control, (B) 30 min
preincubation with 0.6 WM LOX in the presence of 0.5 mg/ml C-4-
S, (C) 30 min incubation with 12/15-LOX after 30 min preincuba-
tion with SMase.
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mass antioxidants [8,9]. However, the subendothelial compart-
ment is rich in such antioxidants from the circulation, like UA
and AscH [3], which can e⁄ciently prevent LDL oxidation
both by metal-catalyzed and by radical-induced mechanisms,
probably even during prolonged retention.
It is quite striking that only the aggregation of C-4-S with
LDL, as shown in this work, can circumvent the antioxidant
protection by antioxidants in metal-catalyzed oxidation, while
C-6-S and enzymatic aggregation proved ine¡ective. It has
been described previously that C-4-S is able to bind Cu2
ions which leads to inhibition of the oxidation of non-aggre-
gated LDL, unlike C-6-S [25] which cannot bind Cu2. Hence,
a possible explanation for the increased sensitivity of C-4-
S/LDL aggregates towards Cu2-mediated oxidation might
be entrapment of comparatively high concentrations of Cu2
within these aggregates, corroborated by the fact that mix-
tures of LL, C-4-S and Cu2 can oxidize after gel-¢ltration:
if Cu2 was not trapped within the complex, it would have
been removed by gel-¢ltration. That C-4-S is responsible for
the binding of Cu2 in these complexes is also supported by
the observation that low concentrations of C-4-S even in-
crease resistance of LDL towards oxidation (Fig. 2B, curve
C), while at higher concentrations (approaching concentra-
tions in the arterial intima) the entrapment e¡ect prevails,
leading to decreased resistance towards oxidation.
These ¢ndings indicate that aggregation or interaction of
glycosaminoglycans and proteoglycans alone with LDL may
not be su⁄cient to increase sensitivity of LDL towards oxi-
dation in the presence of water-soluble antioxidants, as was
originally postulated [8,9], albeit for a system free of such
antioxidants. Neither do other mechanisms of aggregation
increase oxidizability under these conditions, such as shear
forces and the action of enzymes, which do not lead to the
additional incorporation of Cu2 ions. Hence, for the e⁄cient
oxidation of LDL in the presence of AscH and UA, concom-
itant aggregation and entrapment of Cu2 ions is probably a
prerequisite.
Catalytic Cu2 might thus catalyze extensive LDL oxida-
tion protected from the interference by water-soluble antioxi-
dants which would otherwise serve to regenerate the lipophilic
antioxidants in LDL [26]. This is also consistent with our
¢nding that preincubation of LDL with 12/15-LOX greatly
increases the oxidizability of C-4-S/LDL aggregates, while
there was no such e¡ect of 12/15-LOX on pure LDL aggre-
gates prepared by SMase, or on C-6-S/LDL aggregates, and
neither on unaggregated LDL. Lipid hydroperoxides seeded
into LDL by the action of 12/15-LOX become e¡ective only
when they are able to enhance redox-cycling of trapped Cu2,
and when protected from water-soluble antioxidants. The ad-
ditional antioxidant e¡ect observed with SMase might be due
to a general reduction in sensitivity of LDL towards oxidation
by enzymatic cleavage of sphingomyelin [27].
In this work we have described a possible mechanism how
the antioxidant load of plasma or endothelial lining £uid may
be overcome to permit lipid peroxidation processes which
eventually lead to the large amount of oxidized lipid found
in atherosclerotic lesions. The role glycosaminoglycans and
proteoglycans may play in atherogenesis is underlined by re-
cent ¢ndings which indicate that minimally modi¢ed LDL can
induce the secretion of such proteoglycans which increasingly
retain native LDL in the arterial intima [28]. This process
could trigger the increasing accumulation of lipoproteins
which could then be extensively oxidized in the intima even
though in this environment antioxidants are present in abun-
dance.
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